Stocktoria
SUPERNUS PHARMACEUTICALS, INC. SUPN
SUPERNUS PHARMACEUTICALS, INC. (SUPN) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $719.0M at a -5.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.54 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2025-12-19 | Stifel | Hold (main) |
| 2025-10-29 | B of A Securities | Buy (init) |
| 2025-10-23 | TD Cowen | Buy (main) |
| 2025-10-09 | Piper Sandler | Overweight (up) |
| 2025-09-30 | Cantor Fitzgerald | Overweight (main) |
| 2025-08-29 | Piper Sandler | Neutral (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.211 |
| Retained earnings / assets | 0.357 |
| EBIT / assets | -0.043 |
| Equity / liabilities | 2.716 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | 3/9 | 5.11 | — | +8.6% |
| AMPH | Amphastar Pharmaceuticals, Inc. | 6/9 | 4.82 | 9.8 | -1.7% |
| PCRX | Pacira BioSciences, Inc. | 8/9 | 3.08 | 141.1 | +3.6% |
| EBS | Emergent BioSolutions Inc. | 6/9 | 3.44 | 8.4 | -28.8% |
| KNSA | Kiniksa Pharmaceuticals International, plc | 6/9 | 5.08 | 77.2 | +60.1% |
| CORT | CORCEPT THERAPEUTICS INC | 4/9 | 8.97 | 94.1 | +12.8% |
| RARE | Ultragenyx Pharmaceutical Inc. | 4/9 | -9.61 | — | +20.2% |
About SUPERNUS PHARMACEUTICALS, INC.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
FAQ
Is SUPN financially healthy?
SUPERNUS PHARMACEUTICALS, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does SUPN pay a dividend?
No, SUPERNUS PHARMACEUTICALS, INC. does not currently pay a dividend.
How profitable is SUPN?
In FY2025, SUPERNUS PHARMACEUTICALS, INC. had a net margin of -5.4% and a return on equity of -3.6%.
Is SUPN overvalued or undervalued?
SUPERNUS PHARMACEUTICALS, INC. trades at about 36.3× trailing earnings — above its 10-year norm (10-year range 10.9×–1384.0×, median 31.5×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for SUPN?
The average Wall-Street price target for SUPERNUS PHARMACEUTICALS, INC. is $62.83, about 31.3% above the recent price, from 6 analysts.
Is SUPN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on SUPERNUS PHARMACEUTICALS, INC.: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.